TriangleVS-7375 (NCT07644559)
VS-7375 trial for Pancreatic Ductal Adenocarcinoma (PDAC) (NCT07644559). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic pancreatic ductal adenocarcinoma carrying KRAS G12D, confirmed with tissue testing. Prior direct RAS inhibitors are excluded.
The idea: oral VS-7375 targets active and inactive KRAS G12D. Groups receive it alone or with cetuximab; panitumumab may substitute after specified allergy findings. Combination cohorts cover first-line treatment or exactly one prior metastatic treatment line.
This phase 2 study plans 185 patients. Verastem sponsors it, with 27 recruiting US sites. Researchers measure tumor response and safety; a first-line cohort allows up to one prior standard-treatment cycle.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.